Countable Labs, the developer of Countable PCR, a breakthrough single-molecule PCR technology redefining how science measures biology, announced the closing of an oversubscribed $26 million financing round to enable the development of fit-for-purpose solutions leveraging 10-color capabilities to support cell and gene therapy, minimal residual disease testing (MRD), biomarker validation, vaccine quality control, and other applications. Led by ARCH Venture Partners with participation from F-Prime Capital and Primer Ventures, the funding round will also support the company's global commercial expansion under the leadership of newly appointed Vice President of Global Sales, Christopher Citraro.

Countable Labs is transforming how biology is measured- bringing single-molecule precision to cell and gene therapy, oncology, molecular diagnostics, and other applications that demand the highest analytical performance. Countable PCR delivers at least 10 times the sensitivity of conventional PCR, with dynamic range and quantitative accuracy that existing digital PCR and next-generation sequencing approaches have not achieved - enabling detection and quantification of rare targets with a level of confidence that fundamentally changes what's measurable.